Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis

Figure 4

Forest plots of different comparison groups. (a) The OR of rash for all grades checked using the random effect (RE) model in Group E (PD-1 or PD-L1 versus Placebo): subgroup analyses were carried out according to the types of immune checkpoint inhibitors (PD-1 or PD-L1). (b) The OR of rash for all grades checked using the random effect (RE) model in Group E (PD-1 or PD-L1 versus Placebo): subgroup analyses were carried out according to the treatment lines (first or second line). (c) The OR of rash for all grades checked using the random effect (RE) model in Group E (PD-1 or PD-L1 versus Placebo): subgroup analyses were carried out based on tumor type. (d) The OR of rash for all grades checked using the random effect (RE) model in Group E (PD-1 or PD-L1 versus Placebo): subgroup analyses were carried out based on tumor type and I2 value. (e) The OR of rash for all grades checked using the random effect (RE) model in Group F (PD-1 or PD-L1 plus Chemotherapy VS PD-1 or PD-L1): subgroup analyses were carried out according to the types of immune checkpoint inhibitors (PD-1 or PD-L1). (f) The OR of rash for all grades checked using the random effect (RE) model in Group F (PD-1 or PD-L1 plus Chemotherapy versus PD-1 or PD-L1): subgroup analyses were carried out according to the treatment lines (first or second line).

(a)

(b)

(c)

(d)

(e)

(f)